artists if you will.

One does wonder how the BID / ASK did arrive at 1 penny on the morning of October 3rd 2016...bear in mind, the SAMI cappucino video was filmed in March 2015, sum 18 months earlier.  Important to recall that the "FAILED" phase 3 ( advertised only ) is producing about 50% of the required data for the now THRIVING phase 3B ....

Somebody made out like a "bandito"..."7 likes" you say...the Beech Boys, the authors of this little social media affair have thousands of Stockhouse IDs...but too many "likes" would look "?able" 

Just 2 months after the October 3rd affair, THEY ( EDT ) chose to cut-off ALL future news here to the US and allow all the advancement to go "stealth" ....our 20 year actor chose to share the news just minutes after it arrived from his Edmonten HQ ; - ) NOTE his coffin remark

Nasty isn't it? ..the below post brought to you minutes after it was released.  "Viking-fellow" often provides the bullboard with news just minutes after it's release.  Remember Davi-Kling claims to be from Edmonten ( 2 or 3 hours behind us here in the east ), he does get up early to treat those ready to absorb and SHARE the "stories" .....as they say bon appetito!

daviking (158)
User Actions
December 14, 2016 - 08:19 AM
193 Reads
Post# 25596846
Is this another nail in the coffin? What is everyone's take?


Spectral Medical Inc.December 14, 2016 08:00 ET
Spectral Voluntarily Delists From OTCQX
TORONTO, ONTARIO--(Marketwired - Dec. 14, 2016) -Spectral Medical Inc. ("Spectral" or the "Company") (TSX:EDT)(OTCQX:EDTXF), a Phase III company developing the first treatment for patients with endotoxemic septic shock using a medical device, today announced that after a detailed review of the trading volume, costs and administrative requirements related to maintaining the Company's listing on the OTCQX, it has voluntarily delisted its Common shares from the OTCQX effective January 1, 2017. Spectral's Common shares will continue to be listed on the Toronto Stock Exchange.
About Spectral Medical Inc.
Spectral is a Phase III company seeking U.S. FDA approval for its unique product Toraymyxin™ ("PMX") for the treatment of patients with septic shock. PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is directed by the Company's Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis.
PMX has been approved for therapeutic use in Japan and Europe, and has been used safely and effectively on more than 150,000 patients to date. Approximately 350,000 patients are diagnosed with severe sepsis and septic shock in North America each year. Currently there is no specific treatment available for this condition.
Spectral is listed on the Toronto Stock Exchange under the symbol EDT. For more information please visit www.spectraldx.com.
Forward-looking Statement
Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral's senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to commercialize its products, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected.
The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.
Contact Information
Anthony Businskas
Executive Vice President and CFO
Spectral Medical Inc